The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics

Ying-Erh Chou, Po-Jen Yang, Chia-Yen Lin, Yen-Yu Chen, Whei-Ling Chiang, Pei-Xuan Lin, Zih-Yun Huang, Matthew Huang, Yung-Chuan Ho and Shun-Fa Yang
Additional contact information
Ying-Erh Chou: School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Po-Jen Yang: School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Chia-Yen Lin: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Yen-Yu Chen: School of Medical Applied Chemistry, Chung Shan Medical University, Taichung 402, Taiwan
Whei-Ling Chiang: School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan
Pei-Xuan Lin: School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan
Zih-Yun Huang: School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan
Matthew Huang: White Oaks Secondary School, Oakville, ON L6H 1Z5, Canada
Yung-Chuan Ho: Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan
Shun-Fa Yang: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan

IJERPH, 2020, vol. 17, issue 19, 1-11

Abstract: Prostate cancer is one of the major cancers of the genitourinary tract. High-mobility group box 1 (HMGB1) was suggested as a promising therapeutic target for prostate cancer. In this study, we aim to elucidate the associations of HMGB1 single nucleotide polymorphisms (SNPs) with prostate cancer susceptibility and clinicopathological characteristics. The HMGB1 SNPs rs1412125, rs2249825, rs1045411, and rs1360485 in 579 prostate cancer patients and 579 cancer-free controls were analyzed with real-time polymerase chain reactions (real-time PCR). All of the data were evaluated with SAS statistical software. Our results showed that the HMGB1 rs1045411 T allele genotype was significantly associated with advanced pathologic T stage (odds ratio (OR) = 1.433, 95% confidence interval (CI) = 1.021–2.012; p = 0.037) and pathologic N1 stage (OR = 2.091, 95% CI = 1.160–3.767; p = 0.012), and the rs1360485 polymorphic CT + TT genotype was associated with pathologic Gleason grade group (4 + 5) (OR = 1.583, 95% CI = 1.017–2.462; p = 0.041), pathologic T stage (3 + 4) (OR = 1.482, 95% CI = 1.061–2.070; p = 0.021), and pathologic N1 stage (OR = 2.131, 95% CI = 1.178–3.852; p = 0.011) compared with their wild-type carriers. In conclusion, our results revealed that the HMGB1 SNPs were associated with the clinical status of prostate cancer. The HMGB1 SNPs may have the potential to predict prostate cancer disease progression.

Keywords: prostate cancer; HMGB1; polymorphism (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/19/7247/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/19/7247/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:19:p:7247-:d:423553

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().